Updates in the Management of Hepatobiliary Cancers

Presented by:
Mitesh J. Borad
Search for other papers by Mitesh J. Borad in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 21: Issue 5.5
Online Publication Date:
01 Jun 2023
DOI:
https://doi.org/10.6004/jnccn.2023.5021
Restricted access

Hepatobiliary cancers are aggressive tumors that affect the liver and biliary tract and are responsible for nearly 550,000 deaths per year. The most common malignancy is hepatocellular carcinoma, and risk factors include viral hepatitis infection, nonalcoholic steatohepatitis, and excessive alcohol use. Other etiologies include Wilson’s disease, α1-antitrypsin deficiency, and cryptogenic cirrhosis. Clinicians should be aware of underlying conditions and how they influence treatment decisions.

Disclosures: Dr. Borad has disclosed no relevant financial relationships.

Correspondence: Mitesh J. Borad, MD, Mayo Clinic Comprehensive Cancer Center, 13400 East Shea Boulevard, Scottsdale, AZ 85259. Email: borad.mitesh@mayo.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.

  • 2.

    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52:512–519.

  • 4.

    Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–1173.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–1905.

  • 6.

    Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence 2022;1:EVIDoa2100070.

  • 7.

    Cardinale V, Consiglia Bragazzi M, Carpino G, et al. Intrahepatic cholangiocarcinoma: review and update. Hepatoma Res 2018;4:20.

  • 8.

    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–1281.

  • 9.

    Shroff RT, Guthrie KA, Scott AJ, et al. SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol 2023;41(Suppl):Abstract LBA490.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence 2022;1:EVIDoa2200015.

  • 11.

    Lee H, Wang K, Johnson A, et al. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol 2016;69:403–408.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Israel MA, Danziger N, McGregor KA, et al. Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist 2021;26:787–796.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Farshidfar F, Zheng S, Gingras MG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;18:2780–2794.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671–684.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021;6:803–815.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388:228–239.

  • 17.

    Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation. JAMA Oncol 2021;7:1669–1677.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234–1243.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2023 by the National Comprehensive Cancer Network 2023
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2023
Online Publication Date:
01 Jun 2023

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 968 528 148
PDF Downloads 385 122 19
EPUB Downloads 0 0 0